The DSMB clearance to escalate to the highest dose cohort is a strong safety signal that de-risks the program. The November 10 mg/kg data readout is the next major catalyst; a positive readout could significantly re-rate the stock. Monitor for any updates on the FDA partial clinical hold, which remains a risk.
Price Chart
Executive Summary
PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus by 13.3%, with no revenue. The key catalyst is the DSMB's recommendation to advance PGN-EDODM1 into the highest 12.5 mg/kg dose cohort in the FREEDOM2-DM1 study and to dose-escalate the OLE, confirming a favorable safety profile. The company has $117.2M cash, sufficient into Q4 2027, and expects 10 mg/kg data in November 2026, which is the primary near-term catalyst.
Key Financial Metrics
Key Facts
- DSMB recommended advancing FREEDOM2 into the highest 12.5 mg/kg dose cohort with no protocol changes.
- DSMB also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.
- 10 mg/kg FREEDOM2 cohort fully enrolled; 7 of 8 participants completed dosing; data expected November 2026.
- 12.5 mg/kg cohort results expected 1H 2027; EOP2 meeting with regulators planned thereafter.
- Cash, cash equivalents and marketable securities were $117.2M as of June 30, 2026, sufficient into Q4 2027.
- Net loss was $17.8M ($0.26 per share) vs $23.1M ($0.70 per share) in Q2 2025.
- EPS of -$0.26 beat consensus of -$0.30 by 13.3%.
- EMA granted Orphan Designation for PGN-EDODM1.
- No serious adverse events or dose-limiting toxicities reported in FREEDOM2 or OLE to date.
- 16 patients enrolled in FREEDOM-OLE at 5 mg/kg; 6 of 8 from 5 mg/kg FREEDOM2 cohort enrolled.
Financial Impact
EPS beat of 13.3% vs consensus; cash burn of ~$15.1M per quarter; cash runway extended into Q4 2027
Risk Factors
- FDA partial clinical hold on FREEDOM2 study remains unresolved.
- 10 mg/kg data in November may not replicate the splicing correction trends seen at lower doses.
- Dilution risk from potential future equity offerings to fund operations beyond current cash runway.
- Clinical-stage biotech with no approved products or revenue; binary event risk around data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336767 |
| Document: pepg-20260806.htm | 0001193125-26-336767 |
| Document: pepg-ex99_2.htm | 0001193125-26-336767 |
| Document: pepg-ex99_3.htm | 0001193125-26-336767 |
| Document: 0001193125-26-336767-index-headers.html | 0001193125-26-336767 |
| Document: 0001193125-26-336767-index.html | 0001193125-26-336767 |
| Document: 0001193125-26-336767.txt | 0001193125-26-336767 |
| 8-K Data (Synthetic) | 0001193125-26-336767 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.41 $3.18 | ▲ +31.95% | ▲ +31.35% | $2.27 (−6.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
May 22, 2026 19w ago | EFFECT | $1.51 $1.90 | ▼ −25.83% | ▼ −27.24% | $2.27 (−50.00%) |
May 19, 2026 19w ago | S-3 | $1.38 $1.70 | ▼ −23.19% | ▼ −22.20% | $2.27 (−64.13%) |
May 12, 2026 20w ago | 8-K | $1.78 $1.51 | ▼ −15.17% | ▼ −14.56% | $2.27 (+27.25%) |
Mar 4, 2026 30w ago | 8-K | $5.51 $1.73 | ▼ −68.57% | ▼ −64.79% | $2.27 (−58.86%) |
Mar 4, 2026 30w ago | Insider Cluster | $6.76 $1.74 | ▼ −74.26% | ▼ −69.84% | $2.27 (−66.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access